Reaction Details |
| Report a problem with these data |
Target | Serine/threonine-protein kinase PLK2 |
---|
Ligand | BDBM50595386 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_2216623 (CHEMBL5129755) |
---|
IC50 | 242200±n/a nM |
---|
Citation | Zhang, J; Zhang, L; Wang, J; Ouyang, L; Wang, Y Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential. J Med Chem65:10133-10160 (2022) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Serine/threonine-protein kinase PLK2 |
---|
Name: | Serine/threonine-protein kinase PLK2 |
Synonyms: | PLK2 | PLK2_HUMAN | Polo-Like Kinase 2 | SNK | Serine/threonine-protein kinase PLK2 | Serine/threonine-protein kinase SNK | Serum-inducible kinase |
Type: | Serine/threonine-protein kinase |
Mol. Mass.: | 78259.87 |
Organism: | Homo sapiens (Human) |
Description: | Full-length human PLK2 was expressed as GST-fusion protein using baculovirus expression system. GST-PLK2 was purified by using glutathione sepharose chromatography. |
Residue: | 685 |
Sequence: | MELLRTITYQPAASTKMCEQALGKGCGADSKKKRPPQPPEESQPPQSQAQVPPAAPHHHH
HHSHSGPEISRIIVDPTTGKRYCRGKVLGKGGFAKCYEMTDLTNNKVYAAKIIPHSRVAK
PHQREKIDKEIELHRILHHKHVVQFYHYFEDKENIYILLEYCSRRSMAHILKARKVLTEP
EVRYYLRQIVSGLKYLHEQEILHRDLKLGNFFINEAMELKVGDFGLAARLEPLEHRRRTI
CGTPNYLSPEVLNKQGHGCESDIWALGCVMYTMLLGRPPFETTNLKETYRCIREARYTMP
SSLLAPAKHLIASMLSKNPEDRPSLDDIIRHDFFLQGFTPDRLSSSCCHTVPDFHLSSPA
KNFFKKAAAALFGGKKDKARYIDTHNRVSKEDEDIYKLRHDLKKTSITQQPSKHRTDEEL
QPPTTTVARSGTPAVENKQQIGDAIRMIVRGTLGSCSSSSECLEDSTMGSVADTVARVLR
GCLENMPEADCIPKEQLSTSFQWVTKWVDYSNKYGFGYQLSDHTVGVLFNNGAHMSLLPD
KKTVHYYAELGQCSVFPATDAPEQFISQVTVLKYFSHYMEENLMDGGDLPSVTDIRRPRL
YLLQWLKSDKALMMLFNDGTFQVNFYHDHTKIIICSQNEEYLLTYINEDRISTTFRLTTL
LMSGCSSELKNRMEYALNMLLQRCN
|
|
|
BDBM50595386 |
---|
n/a |
---|
Name | BDBM50595386 |
Synonyms: | (2S)-Dihydrobaicalein | CHEMBL402227 |
Type | Small organic molecule |
Emp. Form. | C15H12O5 |
Mol. Mass. | 272.2528 |
SMILES | Oc1cc2O[C@@H](CC(=O)c2c(O)c1O)c1ccccc1 |r| |
Structure |
|